[AA-amyloidosis in inflammatory rheumatic diseases. A report of clinical experiences].
A review of the literature on rheumatic diseases with secondary amyloidosis and our diagnostic and therapeutic experiences in 33 own cases were reported. The place of subcutaneous fat biopsy in the diagnosis of secondary amyloidosis was shown included our own results and the corresponding literature. We saw amyloidosis type AA mostly in patients with high disease activity and progressive stage. There is no sure relationship to the duration of the disease. The renal involvement is clinical most significantly and also most frequently. The renal amyloidosis type AA can be influenced therapeutically however only in normal or unimportant restricted renal function. The therapeutic success is not depended on the choice of the long acting antirheumatic drug. The results were discussed in respect with the current literature.
Schneider
F
F
Rheumaklinik Oberammergau.
D000273:Adipose Tissue / Q000473:pathology; D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000473:pathology*; D001172:Arthritis, Rheumatoid / Q000473:pathology*; D001706:Biopsy; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000685:Serum Amyloid A Protein / Q000032:analysis*; D013167:Spondylitis, Ankylosing / Q000473:pathology*
D000685:Serum Amyloid A Protein
Die AA-Amyloidose bei entzündlich-rheumatischen Erkrankungen. Ein klinischer Erfahrungsbericht.